An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

Inclusion Criteria: * Enrollment within 12 months of completion of Study ALN-GO1-001 * In the opinion of the investigator tolerated the study drug * If taking Vitamin B6 (pyridoxine), willing to remain on a stable regimen for the study duration * Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use a highly effective method of contraception * Willing to provide written informed consent and to comply with study requirements Exclusion Criteria: * Clinically significant health concerns (with the exception of PH1) * Clinically significant cardiovascular abnormality * Abnormal for AST/ALT and any other clinical safety laboratory result considered clinically significant * Requirement for chronic dialysis